Victory Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.17M | Buy |
108,744
+28,015
| +35% | +$2.21M | 0.01% | 1151 |
|
|
2025
Q4 | $6.39M | Buy |
80,729
+62,518
| +343% | +$4.71M | ﹤0.01% | 1225 |
|
|
2025
Q3 | $1.19M | Sell |
18,211
-305
| -2% | -$14.9K | ﹤0.01% | 1760 |
|
|
2025
Q2 | $732K | Sell |
18,516
-125
| -0.7% | -$4.09K | ﹤0.01% | 1959 |
|
|
2025
Q1 | $562K | Buy |
18,641
+637
| +4% | +$20.9K | ﹤0.01% | 2001 |
|
|
2024
Q4 | $629K | Sell |
18,004
-346
| -2% | -$12.9K | ﹤0.01% | 1966 |
|
|
2024
Q3 | $735K | Buy |
18,350
+1,020
| +6% | +$47.5K | ﹤0.01% | 1898 |
|
|
2024
Q2 | $826K | Sell |
17,330
-307
| -2% | -$12.6K | ﹤0.01% | 1787 |
|
|
2024
Q1 | $765K | Sell |
17,637
-10,156
| -37% | -$484K | ﹤0.01% | 1852 |
|
|
2023
Q4 | $1.41M | Buy |
27,793
+12,357
| +80% | +$592K | ﹤0.01% | 1560 |
|
|
2023
Q3 | $700K | Buy |
15,436
+348
| +2% | +$14.4K | ﹤0.01% | 1836 |
|
|
2023
Q2 | $619K | Sell |
15,088
-351
| -2% | -$13.5K | ﹤0.01% | 1898 |
|
|
2023
Q1 | $552K | Sell |
15,439
-348
| -2% | -$13.1K | ﹤0.01% | 1967 |
|
|
2022
Q4 | $596K | Sell |
15,787
-8
| -0.1% | -$336 | ﹤0.01% | 1946 |
|
|
2022
Q3 | $699K | Buy |
15,795
+2,249
| +17% | +$94.8K | ﹤0.01% | 1900 |
|
|
2022
Q2 | $501K | Buy |
13,546
+1,721
| +15% | +$64.9K | ﹤0.01% | 2054 |
|
|
2022
Q1 | $435K | Sell |
11,825
-1,322
| -10% | -$43.3K | ﹤0.01% | 2173 |
|
|
2021
Q4 | $400K | Sell |
13,147
-192
| -1% | -$6.04K | ﹤0.01% | 2267 |
|
|
2021
Q3 | $447K | Sell |
13,339
-877
| -6% | -$33K | ﹤0.01% | 2223 |
|
|
2021
Q2 | $567K | Sell |
14,216
-12,034
| -46% | -$471K | ﹤0.01% | 2139 |
|
|
2021
Q1 | $1.18M | Sell |
26,250
-59,040
| -69% | -$3.29M | ﹤0.01% | 1843 |
|
|
2020
Q4 | $4.82M | Buy |
85,290
+11,553
| +16% | +$576K | 0.01% | 1250 |
|
|
2020
Q3 | $3.5M | Buy |
73,737
+56,637
| +331% | +$3.15M | ﹤0.01% | 1275 |
|
|
2020
Q2 | $1.01M | Sell |
17,100
-18,374
| -52% | -$1.02M | ﹤0.01% | 1732 |
|
|
2020
Q1 | $1.68M | Buy |
35,474
+19,603
| +124% | +$1.09M | ﹤0.01% | 1664 |
|
|
2019
Q4 | $959K | Sell |
15,871
-553
| -3% | -$32.9K | ﹤0.01% | 1767 |
|
|
2019
Q3 | $984K | Buy |
+16,424
| New | +$1.07M | ﹤0.01% | 1706 |
|
|
2017
Q3 | – | Sell |
-591
| Closed | -$30K | – | 1839 |
|
|
2017
Q2 | $30K | Buy |
591
+10
| +2% | +$466 | ﹤0.01% | 1756 |
|
|
2017
Q1 | $23K | Buy |
581
+127
| +28% | +$5.7K | ﹤0.01% | 1762 |
|
|
2016
Q4 | $22K | Buy |
+454
| New | +$18K | ﹤0.01% | 1752 |
|
Other funds holding IONS
VPM
VCM
Victory Capital Management's IONS Position: Q1 2026 in Review
Victory Capital Management increased its Ionis Pharmaceuticals (IONS) stake by 35% in Q1 2026, buying an estimated $2.21M and bringing the position to 108,744 shares worth $8.17M. The position accounts for 0.01% of the portfolio, ranked #1151.
Victory Capital Management first reported a position in IONS in Q4 2016 and has held it in 30 quarters since. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.
- Victory Capital Management held 108,744 shares of Ionis Pharmaceuticals worth $8.17M as of Q1 2026.
- Victory Capital Management bought 28,015 Ionis Pharmaceuticals shares in Q1 2026, an estimated $2.21M.
- Ionis Pharmaceuticals made up 0.01% of Victory Capital Management's portfolio in Q1 2026, its #1151 holding.
- Victory Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2016 and has held it in 30 quarters since.
- 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.
Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.